Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation

Musson, Donald G.; Kitchen, Chester J.; Hsieh, John Y.‐K.; Birk, Kimberly L.

doi:10.1016/s1570-0232(02)00377-x

Cited by 13 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chromatographic methods have been described for the assay of ertapenem and, although these appear to be slightly more sensitive [10] than the method described here, they are more complex. The previously described methods use column switching that requires an advanced system of two pumps and different mobile phases [9,10], which may not be available in many laboratories. In this study, we have been able to develop a simple, straightforward method to assay ertapenem in human serum that is able to detect ertapenem at clinically relevant concentrations.…”

Section: Discussionmentioning

confidence: 99%

“…Although high-performance liquid chromatography (HPLC) methods have been described for ertapenem, these are complex and involve column switching and thus this type of assay may not suitable for use in routine clinical microbiology laboratories [9,10]. In this study we report a rapid, straightforward HPLC method for assay of ertapenem in human serum.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assay of ertapenem in human serum by high-performance liquid chromatography

Soltani¹,

MacGowan²,

Lovering³

2006

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assay of ertapenem in human serum by high-performance liquid chromatography

Soltani¹,

MacGowan²,

Lovering³

2006

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…The capabilities of ertapenem regarding the penetration into tissues or lumina, and the permeation of cell membranes into the inner compartment are expected to differ markedly from imipenem or meropenem and need to be addressed in separate studies which require a broad array of analytical methods. However, only few HPLC/UV methods for the determination of ertapenem in biological matrices are published [3][4][5][6][7][8]. All are based on standard 4.6 mm I.D.…”

Section: Introductionmentioning

confidence: 99%

A new simple HPLC assay for the quantification of ertapenem in human plasma, lung tissue, and broncho-alveolar lavage fluid

Mundkowski

Majcher-Peszynska

Burkhardt

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

“…Fecal flora was evaluated on days Ϫ2 (baseline), Ϫ1 (baseline), 4,8,14,21, and 35, with a washout period of 4 weeks between each treatment period.…”

mentioning

confidence: 99%

“…Serum (ceftriaxone) and plasma (ertapenem) concentration-versus-time data were generated by collecting blood samples (approximately 6 ml each) before infusion (Ϫ0.5 h), at the end of infusion (0 h), and at 0.5, 1, 1.5, 2, 3, 4,6,8,12, and 24 h after the end of infusion for each study drug on day 1 and day 7.…”

mentioning

confidence: 99%

Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers

Pletz

Rau

Bulitta

et al. 2004

Antimicrob Agents Chemother

106

View full text Add to dashboard Cite

The pharmacokinetics of ertapenem and ceftriaxone were investigated in an open, randomized, two-period crossover study after single-and multiple-dose administration in 10 healthy volunteers (five women and five men). Both antibiotics were administered intravenously once daily for 7 days at dosages of 1 g (ertapenem) and 2 g (ceftriaxone). The concentrations of the antibiotics in serum and urine were quantified by the agar well diffusion method bioassay and, in addition, for ertapenem only, by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). For ertapenem the maximum concentration of the drug in plasma (C max ) was 256 mg/liter, the half-life was 20.7 h, and the area under the plasma concentration-time curve (AUC) was 830 mg ⅐ h/ liter. The concentrations in fecal samples were (mean value) 37.2 and 32.7 mg/kg on day 4 and day 8, respectively. Ceftriaxone exhibited a mean C max of 315 mg/liter, a half-life of 7.6 h, and an AUC of 1,556 mg ⅐ h/liter. The mean concentrations in fecal samples were 153 and 258 mg/kg on day 4 and day 8, respectively. No accumulation of ertapenem or ceftriaxone was detected at steady state. A slightly but significantly decreased AUC for ertapenem was detected for the female volunteers. No serious adverse event was observed. Both antibiotics induced a marked decrease in the anaerobic microflora (4-log-unit decreases in lactobacilli, bifidobacteria, clostridia, and bacteroides) and Escherichia coli, whereas the number of enterococci increased (4 log units). A slight overgrowth of yeasts was observed with both regimens. In all cases the microflora returned to normal levels on days 21 to 35.Ertapenem, recently described as the first class 1 carbapenem (11), is a parenteral broad-spectrum beta-1-methyl-carbapenem with a long half-life in serum. It has been shown to be effective for the treatment of community-acquired pneumonia (9); intra-abdominal infections, skin and skin structure infections, and acute pelvic infections (14); and urinary tract infections (15). In contrast to imipenem and meropenem, ertapenem lacks sufficient activity against Pseudomonas aeruginosa, enterococci, and Acinetobacter spp.; but clinical trials have shown that Pseudomonas infections can be treated with ertapenem.Ertapenem can be administered once daily due to its long half-life in plasma. The long half-life in plasma reflects its high level of plasma protein binding.Ceftriaxone matches ertapenem in both its pharmacokinetics and its antibacterial spectrum for the treatment of community-acquired pneumonia and has been used as a comparator drug for ertapenem in clinical trials (9, 17). Ceftriaxone is a broad-spectrum parenteral cephalosporin with a long half-life that also requires administration only once daily.The application of antibacterial agents for the treatment of infections may have a number of potentially adverse effects on the normal oropharyngeal and intestinal microflora. The normal microflora acts as a barrier against colonization by potentially pathogenic microorganisms and agai...

show abstract

Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation

Cited by 13 publications

References 2 publications

Assay of ertapenem in human serum by high-performance liquid chromatography

Assay of ertapenem in human serum by high-performance liquid chromatography

A new simple HPLC assay for the quantification of ertapenem in human plasma, lung tissue, and broncho-alveolar lavage fluid

Ertapenem Pharmacokinetics and Impact on Intestinal Microflora, in Comparison to Those of Ceftriaxone, after Multiple Dosing in Male and Female Volunteers

Contact Info

Product

Resources

About